BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2020 9:59:39 AM | Browse: 611 | Download: 796
 |
Received |
|
2020-07-08 11:40 |
|
Peer-Review Started |
|
2020-07-08 11:41 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-08-11 15:10 |
|
Revised |
|
2020-08-21 16:16 |
|
Second Decision |
|
2020-09-24 12:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-25 05:16 |
|
Articles in Press |
|
2020-09-25 05:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-19 00:54 |
|
Publish the Manuscript Online |
|
2020-10-26 09:59 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jayne Palmer and Oscar R Leeuwenkamp |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jayne Palmer, BSc, DPhil, Doctor, Doctor, NA, Ossian Health Economics and Communications, Bäumleingasse 20, Basel 4051, Switzerland. smith-palmer@ossianconsulting.com |
| Key Words |
Cost; Cost-effectiveness; Neuroendocrine tumors; 177Lu-Dotatate; Sweden; Norway |
| Core Tip |
Peptide receptor radionuclide therapy with 177Lutetium oxodotreotide (177Lu-Dotatate; Lutathera), which targets the overexpression of somatostatin receptors, particularly the somatostatin receptor type 2 expressed on the surface of tumor cells in some neuroendocrine tumors (NETs), is an efficacious new treatment approach for patients with gastroenteropancreatic NETs. To be adopted into routine clinical practices, new treatments should also be cost-effective as well as efficacious. Long-term health economic analyses suggest that in Sweden and Norway 177Lu-Dotate is likely to be cost-effective and associated with minimal budget impact relative to everolimus for the treatment of unresectable or metastatic progressive midgut or pancreatic NETs. |
| Publish Date |
2020-10-26 09:59 |
| Citation |
Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i20/4793.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i20.4793 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
